| 注册
首页|期刊导航|重庆医学|拉米夫定联合阿德福韦酯与恩替卡韦单药对慢性乙型肝炎初治患者疗效比较的Meta分析

拉米夫定联合阿德福韦酯与恩替卡韦单药对慢性乙型肝炎初治患者疗效比较的Meta分析

黄睿 郝迎迎 张俊 吴超

重庆医学Issue(1):9-11,15,4.
重庆医学Issue(1):9-11,15,4.DOI:10.3969/j.issn.1671-8348.2014.01.003

拉米夫定联合阿德福韦酯与恩替卡韦单药对慢性乙型肝炎初治患者疗效比较的Meta分析

Comparison of the efficacy of lamivudine combined adefovir dipivoxil and entecavir monotherapy in the treatment of naive patients with chronic hepatitis B:a Meta analysis

黄睿 1郝迎迎 2张俊 1吴超2

作者信息

  • 1. 南京中医药大学中西医结合鼓楼临床学院,南京210008
  • 2. 南京大学医学院附属鼓楼医院感染科,南京210008
  • 折叠

摘要

Abstract

Objective To analyse the efficacy of lamivudine(LAM) combined adefovir dipivoxil(ADV) and entecavir(ETV) in the treatment of naive patients with chronic hepatitis B (CHB) .Methods Cochrane Library ,MEDLINE ,Web of Science ,CNKI (China National Knowledge Infrastructure ) ,WANFANG database and VIP database were searched and the references of eligible studies were screened .All relevant literatures published before March 6th ,2012 were reviewed .Comparison of the efficacy of lami-vudine combined adefovir dipivoxil and entecavir in the treatment of naive patients with chronic hepatitis B was included and Rev Man 5 .1 software was used for Meta analysis .Results Four eligible studies (587 patients in all) were included for the analysis .In the entecavir monotherapy group ,the serum ALT normalization rate was a little higher at the 12 weeks and 24 weeks of the treat-ment compared to the combination group[OR=0 .52 ,95% CI(0 .28 ,0 .97) ,Z=2 .04 ,P=0 .04] ,[OR=0 .45 ,95% CI(0 .22 ,0 .95) , Z=2 .11 ,P=0 .04] ,respectively .But after 36 weeks there was no significance between the two groups .For HBV DNA undetect-able rate ,there were no significant differences between the two groups at the 12 weeks ,24 weeks ,36 weeks ,48 weeks ,18 months , 24 months and 30 months of the treatment (P=0 .22 ,P=0 .30 ,P=0 .86 ,P=0 .31 ,P=0 .93 ,P=0 .84 and P=0 .83 respectively) . At the 48 weeks ,HBeAg negative rate has no significant difference between the two groups [OR=0 .93 ,95% CI(0 .29 ,2 .95) ,Z=0 .13 ,P=0 .90] .Conclusion Both LAM+ADV combination therapy and ETV monotherapy are effective in the treatment of naive patients with CHB ,but further studies are still needed to obtain long term results and safety by high quality ,large scale randomized controlled trials .

关键词

慢性乙型肝炎/拉米夫定/阿德福韦酯/恩替卡韦/联合治疗/Meta分析

Key words

chronic hepatitis B/lamivudine/adefovir dipivoxil/entecavir/combination treatment/Meta analysis

引用本文复制引用

黄睿,郝迎迎,张俊,吴超..拉米夫定联合阿德福韦酯与恩替卡韦单药对慢性乙型肝炎初治患者疗效比较的Meta分析[J].重庆医学,2014,(1):9-11,15,4.

基金项目

江苏省医学领军人才与创新团队资助项目(LJ201154);南京市医学重点科技发展项目(ZKX09032)。 ()

重庆医学

OA北大核心CSTPCD

1671-8348

访问量0
|
下载量0
段落导航相关论文